News
-
Trials key benefit
Wednesday | Aug 2 2017THE cost of clinical trials looking at gaps in medical evidence is outweighed almost sixfold by the savings that flow from the health improvements experienced by patients, as well as the direct savings to the health system and the wider economy.
-
Hospitals untapped resource
Wednesday | Aug 2 2017THE interim report of the Review of Pharmacy Remuneration and Regulation "fails to acknowledge or leverage the pivotal role of hospital pharmacists in ensuring Australians have appropriate and convenient access to medicines", according to the Society of Hospital Pharmacists of Australia (SHPA).
-
New compounding guideline
Wednesday | Aug 2 2017THE Pharmacy Board of Australia has released its long-awaited guideline on the Compounding of Sterile Injectable Medicines, with the document replacing the section 'Expiry of compounded parental medicines' in the Board's Guidelines on compounding of medicines.
-
-
Dispensary Corner 01 Aug 17
Tuesday | Aug 1 2017AN OHIO defense lawyer is accusing one or more jurors of stealing 71 oxycodone pills that were discovered missing after a drug-possession trial ended last week in a county court.
-
OCD study recruit call
Tuesday | Aug 1 2017CURTIN University researchers have announced they are seeking to recruit parents of children with Obsessive Compulsive Disorder (OCD) to take part in a new study.
-
G&M Integria deal
Tuesday | Aug 1 2017ORGANIC skincare company G&M Cosmetics has announced a distribution agreement with natural medicine company Integria Healthcare.
-
Opdivo broad funding
Tuesday | Aug 1 2017BRISTOL-MYERS Squibb has announced that Opdivo (nivolumab) will be listed on the Pharmaceutical Benefits Scheme (PBS) from 1st August for locally advanced or metastatic non-small cell lung cancer (NSCLC) and advanced (stage IV) clear cell variant renal cell carcinoma (RCC).
-
Homeopathy slammed
Tuesday | Aug 1 2017NHS England has published detailed plans, drawn up with family doctors and pharmacists, to cut out prescriptions for ineffective, over-priced and low value treatments.
-
Alexion income up 21%
Tuesday | Aug 1 2017GLOBAL biopharmaceutical company Alexion, which specialises in life-threatening diseases with little or no effective treatments, has announced 2Q17 total revenues of US$912 million, 21% up over 2Q16, in its NASDAQ report to shareholders.
